Anti-tim-3 antigen antibody or antibody derivative, and use thereof
US-2024391997-A1 · Nov 28, 2024 · US
ZIP12 antibody
US12448441B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12448441-B2 |
| Application number | US-202418989629-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 20, 2024 |
| Priority date | Mar 22, 2022 |
| Publication date | Oct 21, 2025 |
| Grant date | Oct 21, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds ZIP12, and comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 13, a CDR-H2 domain comprising or consisting of SEQ ID No: 14, a CDR-H3 domain comprising or consisting of SEQ ID No: 15, a CDR-L1 domain comprising or consisting of SEQ ID No: 16, a CDR-L2 domain comprising or consisting of SEQ ID No: 17, and a CDR-L3 domain comprising or consisting of SEQ ID No: 18. 2. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 19 and a light chain variable region comprising or consisting of SEQ ID No: 20. 3. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to claim 1 , and optionally a pharmaceutically acceptable vehicle. 4. A polynucleotide sequence encoding the antibody or antigen binding fragment thereof as defined in claim 1 . 5. An expression cassette, a recombinant vector or a host cell comprising a polynucleotide sequence according to claim 4 . 6. A kit comprising an antibody or antigen-binding fragment thereof according to claim 1 .
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Internalization into the cell · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
comprising antibodies · CPC title
Antihypertensives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12448441B2 cover?
- The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.
- Who is the assignee on this patent?
- Ip2Ipo Innovations Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).